Dynavax Technologies Co. (NASDAQ:DVAX) Shares Acquired by Nordea Investment Management AB

Nordea Investment Management AB raised its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 23.0% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 393,781 shares of the biopharmaceutical company's stock after purchasing an additional 73,681 shares during the quarter. Nordea Investment Management AB owned approximately 0.30% of Dynavax Technologies worth $4,924,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in DVAX. Principal Financial Group Inc. grew its holdings in shares of Dynavax Technologies by 4.2% during the first quarter. Principal Financial Group Inc. now owns 767,909 shares of the biopharmaceutical company's stock valued at $9,530,000 after buying an additional 31,002 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in Dynavax Technologies by 67.8% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 25,099 shares of the biopharmaceutical company's stock valued at $311,000 after purchasing an additional 10,143 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Dynavax Technologies by 19.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 140,622 shares of the biopharmaceutical company's stock worth $1,745,000 after purchasing an additional 22,548 shares in the last quarter. Diversified Trust Co raised its stake in shares of Dynavax Technologies by 3.2% in the first quarter. Diversified Trust Co now owns 29,548 shares of the biopharmaceutical company's stock worth $367,000 after purchasing an additional 925 shares during the last quarter. Finally, Congress Asset Management Co. MA lifted its holdings in shares of Dynavax Technologies by 1.3% during the first quarter. Congress Asset Management Co. MA now owns 229,980 shares of the biopharmaceutical company's stock valued at $2,854,000 after purchasing an additional 2,845 shares in the last quarter. 96.96% of the stock is currently owned by institutional investors.

Dynavax Technologies Stock Performance

NASDAQ:DVAX traded down $0.38 on Wednesday, hitting $10.60. The stock had a trading volume of 3,904,031 shares, compared to its average volume of 2,115,724. The business's 50-day simple moving average is $11.47 and its two-hundred day simple moving average is $12.33. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of 176.67 and a beta of 1.28. Dynavax Technologies Co. has a 52-week low of $10.48 and a 52-week high of $15.15. The company has a quick ratio of 14.10, a current ratio of 15.20 and a debt-to-equity ratio of 0.36.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.02). Dynavax Technologies had a return on equity of 1.52% and a net margin of 3.91%. The business had revenue of $50.79 million during the quarter, compared to analysts' expectations of $51.98 million. As a group, research analysts predict that Dynavax Technologies Co. will post 0.12 earnings per share for the current year.

Insider Activity

In related news, Director Francis Cano sold 3,615 shares of the firm's stock in a transaction on Friday, May 31st. The stock was sold at an average price of $11.93, for a total value of $43,126.95. Following the transaction, the director now directly owns 36,905 shares of the company's stock, valued at approximately $440,276.65. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 2.98% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on DVAX. StockNews.com downgraded Dynavax Technologies from a "buy" rating to a "hold" rating in a report on Tuesday, May 28th. HC Wainwright reiterated a "buy" rating and issued a $29.00 price target on shares of Dynavax Technologies in a research note on Friday, June 28th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $25.33.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.